Pharma BD Deal Intelligence
Watson's ~$1.9B all-cash buy of Andrx made it the #3 US generics player, but a $497.8M IPR&D writedown drove a $445M net loss the same year and FTC-forced divestitures blunted the near-term payoff. Watson recovered by 2007 ($2.5B revenue, back to profit) and used the scaled base as a springboard to Actavis (2012) and eventually Allergan.
Andrx made Watson the #3 US generics player, but a $497.8M IPR&D writedown and forced FTC divestitures blunted the near-term payoff before Watson moved on to bigger deals (Actavis 2012, Allergan 2015)
Full analysis, sources & comparables →Andrx shares rose 10.65% while Watson fell 3.06%; Standard & Poor's placed Watson on negative CreditWatch, citing concerns about Andrx's pending FDA…
The FTC challenged the deal over likely competitive harm in 13 generic drug markets and required divestitures before clearance, capping Watson's value capture.
On close, Watson became the #3 US generics company by prescriptions, with 66 pending ANDAs and a $30M annual synergy target - largely from corporate…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Generic pharma, sustained-release drug delivery; $25/share all-cash
Andrx made Watson the #3 US generics player, but a $497.8M IPR&D writedown and forced FTC divestitures blunted the near-term payoff before Watson moved on to bigger deals (Actavis 2012, Allergan 2015)
Assessment window: 15yr post-close.
Andrx specialized in generic versions of difficult-to-replicate, controlled-release branded drugs (e.g., extended-release diltiazem/Cartia XT, metoprolol succinate) plus oral contraceptives and a generics distribution business. The 'disease' here is really branded drug pricing power: generics convert a single high-priced brand into a multi-source commodity once patents expire, with controlled-release formulations being the hardest tier to reverse-engineer.
By the announced close in November 2006, US generics was in active consolidation. Teva's 2006 acquisition of Ivax and Novartis' purchase of Eon Labs had reset scale; Mylan, Watson, Sandoz, and Barr were the next-tier players competing for blockbuster patent-cliff opportunities such as simvastatin (Zocor, June 2006) and sertraline (Zoloft, June 2006). Andrx's edge was technical: its ANDA portfolio of controlled-release products like Cartia XT (generic Cardizem CD diltiazem) was hard for low-cost overseas filers to replicate. Watson, formerly oral-contraceptive heavy, used the deal to add 60+ pending ANDAs and a distribution arm, vaulting to #3 US generics by prescriptions dispensed. The FTC required divestitures of overlapping ANDAs in 13 generic markets before clearance. Strategically the deal, alongside Teva-Ivax and Barr-Pliva, set the stage for the Watson-Actavis-Allergan rollup that would continue through the next decade.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation (this deal) | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2006 deals · Watson Pharmaceuticals (Actavis Inc.) deals